«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年02期

页码:

165-169

栏目:

出版日期:

2018-03-20

文章信息/Info

Title:

Clinical effect of ticagrelor in the treatment of acute ST segment elevation myocardial infarction in patients undergoing coronary artery bypass grafting

作者:

米怀雪; 张申; 马宪鲁

济宁市第一人民医院心外科，济宁 272100

Author(s):

MI Huai-xue;  ZHANG Shen;  MA Xian-lu

Department of Cardiovascular Surgery , Jining The First People’s Hospital, Jining 272100, China

关键词:

替格瑞洛; 氯吡格雷; 冠脉搭桥术; 急性ST段抬高性心肌梗死; 临床效果

Keywords:

ticagrelor;  clopidogrel;  surgical treatment ;  acute ST segment elevation myocardial infarction ;  clinical results

分类号:

R541.4

DOI:

-

文献标志码:

A

摘要:

目的：探讨替格瑞洛在冠脉搭桥术治疗急性ST段抬高性心肌梗死的临床疗效。方法：选取急性 ST段抬高性心肌梗死患者387例。术前冠脉造影证实存在冠脉血管左主干病变或严重弥漫冠脉血管病变的 患者共221例，其中65例行急诊经皮冠状动脉介入（PCI）治疗，40例行溶栓治疗，余116例患者因存在急 诊PCI困难或超过溶栓治疗时间窗，建议限期行冠脉搭桥手术且获家属同意。随机平均分为替格瑞洛组（ 58例）、氯吡格雷组（58例），两组患者术前均予以降低心肌耗氧、改善冠脉供血等对症治疗。氯吡格 雷组术前加用氯吡格雷口服，术后予以氯吡格雷+阿司匹林口服；替格瑞洛组术前加用替格瑞洛口服，术 后予以替格瑞洛+阿司匹林口服。比较两组患者治疗后心电图ST段回落幅度、血小板聚集率变化情况、心 功能指标及心血管不良事件发生率。结果：术后第1、12、24小时替格瑞洛组ST段回落程度大于氯吡格雷 组（P＜0.05）；患者用药 5 d、10 d以及30 d血小板聚集率替格瑞洛组低于氯吡格雷组 （P＜0.05）； 术后第1周左室射血分数、左室舒张末期内径及左室收缩末期内径两组无明显统计学差异（P＜0.05）， 术后第4周左室射血分数、左室舒张末期内径及左室收缩末期内径替格瑞洛组优于氯吡格雷组 （P≤0.05 ；心血管不良事件[不稳定性心绞痛 （UAP）、出血、急性心肌梗死（AMI）、心力衰竭（CF） ]发生率 ，替格瑞洛组低于氯吡格雷组 （P＜0.05）。结论：替格瑞洛可显著提高冠脉搭桥术治疗急性ST段抬高 性心肌梗死患者临床疗效。

Abstract:

Objective: To evaluate the clinical effect of ticagrelor in the treatment for acute STEMI in patients who had undergone CABG.Methods: A total of 387 patients with acute STEMI were selected. Preoperative coronary angiography confirmed the left main coronary artery or diffuse coronary artery lesions in 221 patients, including 65 cases of emergency percutaneous coronary intervention (PCI) treatment, and 40 cases of thrombolytic therapy. Owing to the difficulty of interventional treatment, elective coronary artery bypass grafting surgery, the remaining 116 patients were advised to undergo coronary artery bypass surgery within a period of time and received the consent of their family members.The patients were randomly divided into two groups(each 58 patients): the ticagrelor group and the clopidogrel group. All patients were given preoperative myocardial oxygen consumption,coronary blood supply, anticoagulation, lipid regulation and other symptomatic treatment were improved. Clopidogrel group was treated with clopidogrel before oral administration, clopidogrel and aspirin after oral administration, and Grillo group was given oral administration of oral medicine, and after the operation, oral medication was offered.The decrease of ST segment in ECG, platelet aggregation rate, cardiac function index and cardiovascular adverse events were compared between the two groups after treatment. Results: The ST segment decline of ECG: 1 h, 12 h and 24 h after operation ,ticagrelor group was lower than that of clopidogrel group (P＜0.05). The platelet aggregation rate: after medication 5 d, 10 d and 30 d, ticagrelor group was lower than that of that of clopidogrel group (P ＜0.05); left ventricular ejection fraction, left ventricular end diastolic diameter and left ventricular and systolic diameter: after the first week, no significant difference between two groups was found (P＞0.05), but after 4 weeks, ticagrelor group was higher than that of clopidogrel group(P＜0.05); the incidence rate of cardiovascular adverse events （unstable angina pectoris (UAP), hemorrhage, heart failure (CF), acute myocardial infarction (AMI)）, ticagrelor group were lower than those of clopidogrel group (P＜0.05). Conclusion: After the treatment of ticagrelor,the clinical curative effect is improved significantly, for patients who suffered acute STEMI undergoing CABG.

参考文献/References:

[1] 王晓威,于振海.人工血管搭桥术后或介入治疗术后血管通畅率的研究[J].中国现代普通外科进展 ,2012,15(2):123
[2] 肖志斌,张永,李大连,等.80岁以上高龄患者行冠状动脉旁路移植术临床疗效分析[J].中国循证心 血管医学杂志,2014,6(6):724
[3] 周力,陈晖,李敏,等.合并血小板减少的冠心病患者血运重建和抗血小板治疗及随访[J].实用医学 杂志,2014,30(23):3810
[4] Xue H J, Shi J, Liu B, et al. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS[J]. Platelets, 2016, 27(5):440
[5] 贾珠银,瞿小丹,孙家驹,等.替格瑞洛对非ST段抬高急性冠状动脉综合征患者冠状动脉微循环的影 响[J].中国介入心脏病学杂志,2016,24(5):256
[6] Li H, Butler K, Yang L, et al. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two- cohort, single-centrestudy[J]. Clin Drug Investig, 2012,32(2):87
[7] 刘然，师树田，索旻，等.对氯吡格雷低反应患者换用替格瑞洛后的有效性与安全性评价[J].中 国介入心脏病学杂志，2014，22(1):12
[8] Kork F, Balzer F, Spies C D, et al. Minor postoperative increases of creatinine are associated with higher mortality and longer hospital length of stay in surgical patients [J]. Anesthesiology,2015,123(6):1301
[9] 张晋伟,黄方炯,杨禁非,等.术前双联抗血小板药物治疗对非体外循环冠状动脉旁路移植术围手术 期出血的影响[J].中华医学杂志,2015,95(24):1934
[10] 肖苍松,王嵘,李伯君,等.急诊冠状动脉搭桥救治急性冠状动脉综合征及中期随访[J].南方医科大 学学报,2014,13(5):679
[11] 张爱玲,刘瑶,杨莉萍,等.经皮冠状动脉介入术后再发不良心血管事件的影响因素分析[J].药物不 良反应杂志,2014,13(6):350
[12] Jneid H, Anderson J L, Wright R S, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction(updating the 2007 guideline and replacing the 2011focusd update):a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideline[J]. J Am Coll Cardiol,2012,60(7):645
[13] Mega J L, Close S L, Wiviott S D. Cytochrome P-450 polymorphisms and response to clopidogrel[J]. J Vasc Surg, 2009,49 (4):1083
[14] Niu X, Mao L, Huang Y, et al. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta- analysis[J]. J Huazhong Univ Sci Technolog Med Sci, 2015,35(2):147
[15] Aradi D, Komócsi A, Vorobcsuk A, et al. Prognostic significance of high on- clopidogrel platelet reactivity after percutaneous coronary intervention:systematic review and meta-analysis[J]. Am Heart J,2010,160(3):543
[16] Gurbel P A, Bliden K P, Butler K, et al. Response to ticagrelor in clopidogrelnonresponders and responders and effect of switching therapies: the RESPOND study[J]. Circulation, 2010,121(10):1188
[17] 杨影红,孙鑫,田野.替格瑞洛增强腺苷生物学效应的研究进展[J].临床心血管病杂志,2015,31 (2):122
[18] Thomas M R, Outteridge S N, Ajjan R A, et al. Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model[J]. Arterioscler ThrombVasc Biol, 2015, 35(12):2562
[19] Wallentin L, Becker R C, Budaj A, et al. Ticagrelorversusclopidogrel in patients with acute coronary syndromes[J]. NEngl J Med, 2009, 361:1045
[20] Jeong Y H, Smith S C, Gurbel P A. Long-term use of ticagrelor in patients with prior myocardial infarction[J].N Engl J Med, 2015, 373(13):1273
[21] 任晓楠,王明生,赵霞,等.替格瑞洛与氯吡格雷在行冠状动脉介入治疗的不稳定型心绞痛患者中血 小板功能抑制及临床疗效和安全性的研究[J].中华临床医师杂志:电子版,2015,9(17):3294
[22] Levine G N, Jeong Y H, Goto S, et al. World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI[J]. Glob Heart, 2014,9(4):457
[23] Kozinski M, Bielis L, Wisniewska-Szmyt J, et al. Diurnal variation in platelet inhibition by clopidogrel[J]. Platelets, 2011,22(8):579

相似文献/References:

[1]田珺琪,张志广,李 熳,等.双联抗血小板药物对大鼠小肠的损伤及其机制[J].天津医科大学学报,2014,20(05):0.
　TIAN Jun-qi,ZHANG Zhi-guang,LI Man,et al.Dual antiplatelet drugs-induced small intestinal injury and its possible mechanism in rats[J].Journal of Tianjin Medical University,2014,20(02):0.
[2]田珺琪,张志广,李 熳,等.双联抗血小板药物对大鼠小肠的损伤及其机制[J].天津医科大学学报,2014,20(05):0.
　TIAN Jun-qi,ZHANG Zhi-guang,LI Man,et al.Dual antiplatelet drugs-induced small intestinal injury and its possible mechanism in rats[J].Journal of Tianjin Medical University,2014,20(02):0.
[3]田珺琪,张志广,李 熳,等.双联抗血小板药物对大鼠小肠的损伤及其机制[J].天津医科大学学报,2014,20(05):350.
　TIAN Jun-qi,ZHANG Zhi-guang,LI Man,et al.Dual antiplatelet drugs-induced small intestinal injury and its possible mechanism in rats[J].Journal of Tianjin Medical University,2014,20(02):350.
[4]田珺琪,张志广,李 熳,等.双联抗血小板药物对大鼠小肠的损伤及其机制[J].天津医科大学学报,2014,20(05):350.
　TIAN Jun-qi,ZHANG Zhi-guang,LI Man,et al.Dual antiplatelet drugs-induced small intestinal injury and its possible mechanism in rats[J].Journal of Tianjin Medical University,2014,20(02):350.
[5]王 珂,石继红,魏振衡.替格瑞洛、氯吡格雷对急性冠脉综合征患者PCI术后血小板聚集率、血流动力学及免疫功能的影响[J].天津医科大学学报,2020,26(01):35.
　WANG Ke,SHI Ji-hong,WEI Zhen-heng.The effects of Ticagrelor and Clopidogrel on platelet aggregation rate, hemodynamics and immunologic function in patients with acute coronary syndrome after PCI[J].Journal of Tianjin Medical University,2020,26(02):35.

备注/Memo

备注/Memo:

文章编号 １００６－８１４７（２０18）０2-0165-05
作者简介 米怀雪（1986-），男，医师，硕士，研究方向：心脏病及大血管疾病的外科临床；通信作者：张申，E-mail：zhangshen138@sina.com。

常用功能

更新日期/Last Update: 2018-03-20